Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Opnurasib - Novartis

Next Previous
X
Search
Drug Profile

Opnurasib - Novartis

Alternative Names: JDQ-443

Latest Information Update: 18 Oct 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Class Antineoplastics; Azetidines; Chlorobenzenes; Indazoles; Ketones; Pyrazoles; Small molecules; Spiro compounds
  • Mechanism of Action KRAS protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Non-small cell lung cancer
  • Phase I/II Solid tumours
  • Phase I Small cell lung cancer

Most Recent Events

  • 08 Oct 2024 Novartis terminates the phase I trial in Hepatic impairment in USA (PO) (NCT05329623)
  • 01 Aug 2024 Novartis plans to file a regulatory application for Non-small cell lung cancer (Combination therapy) in or after 2027 (Novartis 2023, Annual report)
  • 29 May 2024 Novartis withdraws a phase II trial prior to enrollment in Non small cell lung cancer (Metastatic disease) (NCT05999357) (EudraCT2023-505721-13-00)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top